FAQ on Oragenics Inc.'s $20 Million Preferred Stock and Warrant Offering

What is Oragenics Inc. announcing?

Oragenics Inc. is announcing a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, with gross proceeds potentially totaling $20 million.

Why is Oragenics Inc. raising $20 million?

The funds will support ONP-2 concussion trials, research and development, repayment of a $3 million bridge note, and general corporate needs.

How does the preferred stock and warrant offering work?

Each unit is priced at $25.00, consisting of one share of Series H Convertible Preferred Stock and one Warrant, which allows the purchase of an additional Preferred share at $25.00, convertible into common stock at $2.50.

Who is acting as the sole placement agent for this offering?

Dawson James Securities, Inc. is acting as the sole placement agent for this offering.

When is the closing of this offering expected?

The closing of this offering is expected on or about July 2, 2025.

What is Oragenics Inc.’s focus?

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including treatments for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC).

Where can I find more information about Oragenics Inc.?

For more information, visit the company’s website at www.Oragenics.com or the latest news and updates relating to OGEN in the company’s newsroom at https://ibn.fm/OGEN.

What are the implications of this offering for investors?

This offering provides investors with an opportunity to participate in Oragenics Inc.’s growth through preferred stock and warrants, supporting the company’s R&D efforts and potential advancements in treating neurological disorders and infectious diseases.